AM
AMBBY.US Ambu A/S
- Market cap
- USD 3.47B
- P/E
- 35.0x
- P/B
- 3.63x
- ROE
- 10.3%
- Dividend yield
- 0.65%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2026.
Is AMBBY.US undervalued?
Graham numberAMBBY.US trades 137.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ambu A/S fundamental analysis
No fundamental analysis for Ambu A/S yet.
Ambu A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring pr…
Full company profileAmbu A/S financial statements
Ambu A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.36B | 2.61B | 2.82B | 3.57B | 4.01B | 4.44B | 4.78B | 5.39B | 5.69B | 6.47B |
| Gross Profit | 1.33B | 1.55B | 1.64B | 2.21B | 2.50B | 2.55B | 2.71B | 3.20B | 3.18B | 3.89B |
| Operating Income | 450M | 563M | 499M | 428M | 340M | 144M | 302M | 645M | 738M | 851M |
| EBITDA | 531M | 683M | 542M | 609M | 556M | 435M | 644M | 694M | 1.09B | 1.27B |
| Net Income | 301M | 337M | 317M | 241M | 247M | 93.0M | 168M | 235M | 574M | 642M |
| EPS | 1.24 | 1.36 | 1.28 | 0.97 | 0.98 | 0.37 | 0.64 | 0.88 | 2.15 | 2.42 |
| Balance Sheet | ||||||||||
| Total Assets | 2.50B | 4.23B | 4.56B | 4.93B | 5.74B | 7.22B | 6.86B | 7.15B | 7.69B | 8.22B |
| Total Liabilities | 1.22B | 2.35B | 2.38B | 2.55B | 1.79B | 2.95B | 1.47B | 1.56B | 1.64B | 1.97B |
| Shareholders' Equity | 1.28B | 1.88B | 2.18B | 2.37B | 3.95B | 4.26B | 5.39B | 5.59B | 6.05B | 6.25B |
| Cash & Short-term Investments | 19.0M | 63.0M | 120M | 98.0M | 64.0M | 187M | 157M | 615M | 868M | 536M |
| Total Debt | 786M | 1.31B | 1.16B | 1.44B | 823M | 1.85B | 584M | 558M | 548M | 593M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 462M | 554M | 533M | 295M | 328M | 95.0M | 518M | 813M | 745M | 1.07B |
| Capital Expenditure | 159M | 2.00M | 261M | 430M | 584M | 558M | 326M | 289M | 110M | 578M |
| Free Cash Flow | 303M | 552M | 272M | -135M | -256M | -463M | 192M | 524M | 635M | 487M |
| Ratios | ||||||||||
| ROE | 23.5% | 17.9% | 14.5% | 10.2% | 6.3% | 2.2% | 3.1% | 4.2% | 9.5% | 10.3% |
| ROA | 12.0% | 8.0% | 7.0% | 4.9% | 4.3% | 1.3% | 2.4% | 3.3% | 7.5% | 7.8% |
| Net Profit Margin | 12.8% | 12.9% | 11.2% | 6.8% | 6.2% | 2.1% | 3.5% | 4.4% | 10.1% | 9.9% |
| Debt to Equity | 0.61x | 0.70x | 0.53x | 0.61x | 0.21x | 0.43x | 0.11x | 0.10x | 0.09x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ambu A/S dividends
- Dividend yield
- 0.65%
- Forward dividend
- 0.08 USD
- Payout ratio
- 17.1%
- Ex-dividend date
- Dec 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | DKK 110M | 0.41 | 17.1% |
| 2025 | DKK 95.0M | 0.36 | 16.6% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | DKK 75.0M | 0.29 | 80.6% |
| 2021 | DKK 73.0M | 0.29 | 29.6% |
| 2020 | DKK 96.0M | 0.39 | 39.8% |
| 2019 | DKK 98.0M | 0.40 | 30.9% |
| 2018 | DKK 92.0M | 0.37 | 27.3% |
| 2017 | DKK 75.0M | 0.31 | 24.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 125:100 on Jan 24, 2018.
Who owns Ambu A/S
Ownership data of Ambu A/S is not available yet.
Ambu A/S company profile
- Company name
- Ambu A/S
- Ticker
- AMBBY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,664
- Fiscal year end
- September
- Address
- Baltorpbakken 13, Ballerup, Denmark, 2750
- Phone
- 45 72 25 20 00
- Website
- ambu.com
About Ambu A/S
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, resuscitators, extrication collars, video laryngoscopes. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
Ambu A/S management
10- Ms. Britt Meelby JensenChief Executive Officer · born 1973
- Mr. Henrik Skak BenderChief Financial Officer · born 1984
- Holger HesseFounder
- Ms. Graziela Chaluppe dos Santos MalucelliChief Operations Officer · born 1973
- Mr. Finn MohringChief Technology Officer · born 1965
- Ms. Elisabeth Decou Bedell CliveHead of Investor Relations
- Ms. Tine Bjorn SchmidtHead of Corporate Communications
- Mr. Jesper Johnsen SteenChief Marketing Officer · born 1982
- Ms. Sanne Kjærsgaard HjordrupChief People & Culture Officer · born 1977
- Mr. Thomas Lykke HenriksenHead of HR Systems · born 1973